Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Status:
Completed
Trial end date:
2020-04-17
Target enrollment:
Participant gender:
Summary
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer.
Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive
inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal
growth factor receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer
by simultaneous inhibition of these receptors. The purpose of this study is to determine the
safety and efficacy of Varlitinib in combination with capecitabine for the treatment of
Biliary Tract Cancer. Treatment groups are Varlitinib+capecitabine and Placebo + capecitabine